Answers are grounded in this paper and cite their sources.
Results show the long-term efficacy and durability of brolucizumab in improving visual and anatomical outcomes in DME; the overall safety profile of brolucizumab remained unchanged through year 2.
No takes yet. Share an insight, caveat, or question.
Wykoff et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: